Effects of thiazolidinediones on bone loss and fracture
- PMID: 17940125
- DOI: 10.1345/aph.1K286
Effects of thiazolidinediones on bone loss and fracture
Abstract
Objective: To examine the evidence regarding the effects of thiazolidinediones on bone loss and fracture.
Data sources: Published studies assessing the effects of thiazolidinediones on bone and/or fracture risk in humans were selected for review. A MEDLINE (1950-April 2007) and International Pharmaceutical Abstracts (1970-April 2007) search was performed. Search terms included thiazolidinediones, rosiglitazone, pioglitazone, troglitazone, bone, bone mineral density, fracture, and osteoporosis.
Study selection and data extraction: The literature search retrieved 5 English-language studies evaluating the effects of thiazolidinediones on bone in humans. These consisted of 2 small, uncontrolled studies using troglitazone; 1 prospective, randomized controlled study and 1 retrospective cohort study using rosiglitazone; and a post hoc analysis of an observational cohort study in subjects taking various thiazolidinediones. All of the studies assessed markers of bone metabolism and/or bone mineral density (BMD). No studies were identified that addressed rate of fractures in subjects taking thiazolidinediones.
Data synthesis: The first troglitazone study demonstrated a decrease in levels of bone formation markers (10%; p < 0.05) and resorption markers (12%; p < 0.01), and authors determined that troglitazone produces a protective effect on bone through decreased bone turnover. The second troglitazone study did not demonstrate a significant change in BMD or levels of bone turnover markers. The 2 rosiglitazone studies demonstrated decreases in BMD of 1.19-1.9% with rosiglitazone use (p < 0.05). The post hoc analysis with various thiazolidinediones indicated a 2.5-fold greater decrease in BMD in women reporting thiazolidinedione use.
Conclusions: Few studies have assessed the effects of thiazolidinediones on bone in humans. Studies available suggest that treatment with thiazolidinediones, primarily rosiglitazone, contributes to bone loss. The effect appears to be most prominent in postmenopausal women. More studies are needed to better understand the effects of thiazolidinediones on bone and fracture rates.
Similar articles
-
The effect of thiazolidinediones on BMD and osteoporosis.Nat Clin Pract Endocrinol Metab. 2008 Sep;4(9):507-13. doi: 10.1038/ncpendmet0920. Nat Clin Pract Endocrinol Metab. 2008. PMID: 18695700 Review.
-
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.Calcif Tissue Int. 2010 May;86(5):343-9. doi: 10.1007/s00223-010-9352-5. Epub 2010 Mar 31. Calcif Tissue Int. 2010. PMID: 20354684 Clinical Trial.
-
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.J Endocrinol. 2004 Oct;183(1):203-16. doi: 10.1677/joe.1.05723. J Endocrinol. 2004. PMID: 15525588
-
Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.Clin Endocrinol (Oxf). 2010 Sep;73(3):305-12. doi: 10.1111/j.1365-2265.2010.03784.x. Epub 2010 Feb 10. Clin Endocrinol (Oxf). 2010. PMID: 20148906 Clinical Trial.
-
[Thiazolidinediones and skeletal health].Rev Med Suisse. 2009 Jun 10;5(207):1309-10, 1312-3. Rev Med Suisse. 2009. PMID: 19626930 Review. French.
Cited by
-
Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.Front Endocrinol (Lausanne). 2021 Oct 14;12:735824. doi: 10.3389/fendo.2021.735824. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34721294 Free PMC article.
-
Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease.Drugs. 2019 Jan;79(1):75-84. doi: 10.1007/s40265-018-1040-1. Drugs. 2019. PMID: 30588564 Review.
-
Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies.J Clin Transl Hepatol. 2018 Jun 28;6(2):168-174. doi: 10.14218/JCTH.2017.00050. Epub 2018 Mar 25. J Clin Transl Hepatol. 2018. PMID: 29951362 Free PMC article. Review.
-
Effect of Pioglitazone on Cardiometabolic Risk in Patients With Obstructive Sleep Apnea.Am J Cardiol. 2017 Apr 15;119(8):1205-1210. doi: 10.1016/j.amjcard.2016.12.034. Epub 2017 Jan 25. Am J Cardiol. 2017. PMID: 28219664 Free PMC article.
-
The Effect of Baicalin as A PPAR Activator on Erythroid Differentiation of CD133(+)Hematopoietic Stem Cells in Umbilical Cord Blood.Cell J. 2015 Spring;17(1):15-26. doi: 10.22074/cellj.2015.508. Epub 2015 Apr 8. Cell J. 2015. PMID: 25870831 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
